PEDIATRIC ACUTE CHEST SYNDROME (ACS)

Patients with sickle cell disease presenting with 1) a new pulmonary infiltrate on chest radiography AND 2) evidence of lower airway disease (e.g. cough, shortness of breath, retractions, rales, etc.)

TABLE OF CONTENTS

Algorithm- N/A
Target Population
Background | Definitions
Initial Evaluation-N/A
Clinical Management
Diagnostic Tests
Fluids | Nutrition
Respiratory Therapy
Table 1. Pediatric Asthma Score
Treatment
Table 2. Antimicrobial Medication
Table 3. Pain Medication
Table 4. Respiratory Medication
Discharge Criteria
References
Clinical Improvement Team

TARGET POPULATION

Inclusion Criteria

- Patients with sickle cell disease (SS, SC, Sβ0 thalassemia, Sβ+ thalassemia)
- Patients of all ages
- Patients treated year round

Exclusion Criteria

- Patients without infiltrate on chest radiograph (e.g. asthma exacerbation)
- Patients with severe pulmonary hypertension
- Patients post bone marrow transplant
- Well children with pneumonia
BACKGROUND | DEFINITIONS

Acute chest syndrome (ACS) is the second most common reason for hospitalization in children with sickle cell disease and a leading cause of mortality. ACS is defined as a new pulmonary infiltrate on chest radiograph in the presence of evidence of lower respiratory tract disease (e.g. some combination of cough, shortness of breath, retractions, rales, etc.). In the majority of cases of ACS, an etiology is unable to be identified. The most common identified etiology of ACS is infection but it may also result from pulmonary vaso-occlusion, pulmonary infarction or fat embolism. The primary infectious agents implicated in ACS include: Chlamydia pneumoniae, Mycoplasma pneumoniae, Streptococcus pneumoniae, and viruses. Risk factors for ACS include vaso-occlusive pain crisis, anesthesia, and surgery. Patients are at increased risk for stroke in the two weeks immediately following an episode of ACS.

CLINICAL MANAGEMENT

- Hospitalize on hematology service
- Vital signs q 2-4 hours depending upon degree of respiratory compromise
- Record pain score every 4 hours
- Continuous cardiorespiratory monitor and pulse oximetry
- Encourage ambulation: out of bed to chair or ambulating at least 2-3 times per day
- Droplet precautions
- Continue medication for reactive airway disease if applicable

DIAGNOSTIC TESTS

- CBC with differential, platelet count, and reticulocyte count initially and daily until improving (compare with patient's baseline values)
- CXR initially, repeat for clinical deterioration (be aware that the x-ray often underestimates the degree of involvement and may appear worse when the child is clinically improving)
- Consider:
  - Type and crossmatch for severe illness or if Hb is greater than 1 g/dL below baseline. Request minor-antigen-matched, sickle-negative, leukocyte-depleted RBC
  - Blood cultures if febrile (greater than or equal to 38.3˚C) or history of recent fever (do not need to repeat daily)
  - Arterial blood gas per clinical discretion
  - Renal (BUN, creatinine) and liver (fractionated bilirubin, ALT) function tests for severe illness or if diffuse encephalopathy present (rule out acute multi-organ failure syndrome)
  - If severe abdominal pain consider an ultrasound for gallstones
  - Influenza A& B screening during the appropriate season
  - We do not recommend routinely sending a respiratory pathogen PCR
- Echocardiography is not recommended routinely in patients with acute chest syndrome. Consult cardiology if concern for pulmonary hypertension arises (prolonged hypoxemia, fixed split S2 or pronounced pulmonary component of S2, hepatomegaly, persistent peripheral edema, or persistent pulmonary edema despite adequate fluid status)

FLUIDS | NUTRITION

- Daily weight
- Record intake and output strictly
• Maintain "euvolemia". IV + P.O. = 1 x maintenance. More fluid is appropriate only if patient is dehydrated or if insensible losses are increased (e.g. persistent fever). IV fluid should be D5 1/4 NS to avoid exacerbating the sickling process.

RESPIRATORY THERAPY

• Consult pulmonology
• Clinical features suggestive of asthma or acute bronchospasms make an initial assessment using the Pediatric Asthma Score (PAS); trial Albuterol 4 puffs with a spacer or 2.5 mg nebulized once. Reassess using the PAS, a positive response is a decrease of 2 or more in the PAS. If a positive response is noted, order Albuterol 2-4 puffs or Albuterol 2.5mg nebulized Q4 and PRN. If at any time PAS worsens by 2 or more increase frequency of the Albuterol and notify the provider
• Lung expansion strategies: EzPAP (along with IS) Q4 hours for 72 hours. After 72 hours of the initiation of the therapy, the patient will be evaluated by the respiratory therapist for pulmonary stability. If the chest x-ray (if done) remains stable, there are no signs of pulmonary infection, there is good aeration throughout all lung fields upon auscultation, and the patient can consistently achieve 14ml/kg with the IS, the EzPAP will then be discontinued. The patient will then receive IS Q2 hours while awake and Q4 hours at night by their RN
• Transfer to the ICU if patient is requiring Heated High Flow Nasal Cannula (HHFNC), invasive or non-invasive (CPAP, BiPAP) mechanical ventilation is being considered

TABLE 1. PEDIATRIC ASTHMA SCORE

<table>
<thead>
<tr>
<th>Score</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Respiratory Rate</strong></td>
<td>34 or less</td>
<td>35 to 39</td>
<td>40 or greater</td>
</tr>
<tr>
<td>2 to 3 years</td>
<td>30 or less</td>
<td>31 to 35</td>
<td>36 or greater</td>
</tr>
<tr>
<td>4 to 5 years</td>
<td>26 or less</td>
<td>27 to 30</td>
<td>31 or greater</td>
</tr>
<tr>
<td>6 to 12 years</td>
<td>23 or less</td>
<td>24 to 27</td>
<td>28 or greater</td>
</tr>
<tr>
<td>Older than 12 years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Oxygen Requirements</strong></td>
<td>Greater than 90% on room air</td>
<td>85% to 90% on room air</td>
<td>Less than 85% on room air</td>
</tr>
<tr>
<td><strong>Auscultation</strong></td>
<td>Normal breath sounds to end-expiratory wheeze only</td>
<td>Expiratory wheezing</td>
<td>Inspiratory and expiratory wheezing to diminished breath sounds or poor aeration</td>
</tr>
<tr>
<td><strong>Retractions</strong></td>
<td>Zero to one site</td>
<td>Two sites</td>
<td>Three or more sites</td>
</tr>
<tr>
<td><strong>Dyspnea</strong></td>
<td>Speaks in sentences, coos and babbles</td>
<td>Speaks in partial sentences, short cry</td>
<td>Speaks in single words/ short phrases/grunting</td>
</tr>
</tbody>
</table>

Note: Use PAS Score to guide intervention & response to treatment. Older pediatric
TREATMENT

• Antipyretics
  o Acetaminophen dose according to manufacturer’s recommendations PRN temperature greater than or equal to 38.3°C after blood cultures have been obtained on at least one occasion

• Antibiotics (see Table 2 for choices and doses)
  o Ceftriaxone and azithromycin is the regimen of choice for initial inpatient management
    o If a respiratory pathogen PCR is sent for another reason and is negative for *Mycoplasma* and *Chlamydia*, azithromycin may be discontinued
    o If there is a known or suspected cephalosporin allergy, levofloxacin is the regimen of choice and azithromycin can be omitted because levofloxacin has adequate coverage of atypical organisms
    o Strongly consider adding vancomycin for severe illness, or if large infiltrate with pleural effusion present and *S. aureus* is suspected
  o Prophylactic penicillin should be discontinued while patient is receiving antibiotics
  o If antibiotics are continued upon discharge, an appropriate oral antibiotic should be continued to complete a course of 7-10 days (including inpatient IV therapy received): Amoxicillin-clavulanate is recommended as first line, cefpodoxime is the drug of choice in the presence of a penicillin allergy, and levofloxacin is the drug of choice in the presence of a cephalosporin allergy.

• Analgesia (if indicated)
  o If pain is present patients should be started on scheduled anti-inflammatories and opiates if there are no contraindications
    o Start ketorolac, but limit to 48 hour maximum duration then start ibuprofen PO q6h (not PRN) if no contraindication present (i.e. gastritis, ulcer, coagulopathy, renal impairment).
    o If pain does not respond to anti-inflammatory alone, consult the sickle cell vaso-occlusion guidelines. Be aware narcotic administration may further suppress respiration

• Transfusions
  o Give simple blood transfusion (10 mL/kg red blood cells) to improve oxygen carrying capacity to people with symptomatic ACS whose hemoglobin concentration is greater than 1 g/dL below baseline and hemoglobin would not rise to more than 10 g/dL. If baseline hemoglobin is 9 g/dL or higher, may require red cell exchange transfusion. Do not transfuse acutely to Hb greater than 10 g/dL, Hct greater than 30 percent if percent sickle hemoglobin is or is presumed to be greater than 30 percent since it is associated with inducing pain and stroke
  o Urgent exchange transfusion may be indicated after consultation from hematology, critical care, and apheresis specialists – when there is rapid progression of ACS as manifested by oxygen saturation below 90 percent despite supplemental oxygen, increasing respiratory distress, progressive pulmonary infiltrates, and/or decline in hemoglobin concentration despite simple transfusion and/or inability to transfuse due to high baseline hemoglobin. May require transfer to ICU and transfusion medicine consult for erythrocytapheresis. Remove femoral or central venous catheters as soon as possible after exchange transfusion to reduce risk of thrombosis
TABLE 2. ANTIMICROBIAL MEDICATIONS

<table>
<thead>
<tr>
<th>Medication</th>
<th>Dosing</th>
<th>Indication/Notes</th>
</tr>
</thead>
</table>
| Amoxicillin-clavulanate (PO)| 90 mg/kg/day (maximum 3,000 mg/day if using suspension and 2,625 mg/day if using tablet) PO divided TID | Antimicrobial – Outpatient 1st Choice  
Use either amoxicillin-clavulanate ES suspension 600-42.9mg/5mL or 875-125 mg tablet formulations |
| Azithromycin (IV/PO)        | 10 mg/kg/day (maximum 500 mg/day) PO x 1 dose, followed by 5 mg/kg/day (maximum 250 mg/day) PO once daily x 4 doses | Antimicrobial – Inpatient/Atypical Coverage  
Discontinue if RPP results negative for Chlamydia and Mycoplasma  
Not necessary to use azithromycin with levofloxacin as levofloxacin covers atypical bacteria |
| Cefpodoxime (PO)            | 10 mg/kg/day (maximum 400 mg/day) PO divided BID                      | Antimicrobial – Outpatient for penicillin allergy  
*Ensure prescription sent in advance (variable stock at some outpatient pharmacies) |
| Ceftriaxone (IV)            | 50 mg/kg/day (maximum 2,000 mg/day) IV q24h                           | Antimicrobial – Inpatient 1st Choice  
Discontinue prophylactic penicillin while patient is receiving broad-spectrum antimicrobials |
| Levofloxacin (IV/PO)        | Less than 5 years: Levofloxacin 20 mg/kg/day (maximum 750 mg/day) IV or PO divided q12h  
Greater than or equal to 5 years: 10 mg/kg/day (maximum 750 mg/day) IV or PO q24h | Antimicrobial – Inpatient and/or Outpatient for cephalosporin allergy  
Discontinue prophylactic penicillin while patient is receiving broad-spectrum antimicrobials  
Not necessary to use azithromycin with levofloxacin as levofloxacin covers atypical bacteria |
| Vancomycin (IV)             | Contact pharmacy for recommended dosing  
Dosing interval based on age/renal function)                          | Antimicrobial – Inpatient for patients with severe illness or with large infiltrate with pleural effusion present and S. aureus suspected  
*Must monitor renal function (Scr, BUN, urine output) at baseline and minimum twice weekly thereafter |
**TABLE 3. RESPIRATORY MEDICATION TABLE**

<table>
<thead>
<tr>
<th>Medication</th>
<th>Dosing</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Albuterol</strong></td>
<td>4 puffs OR 2.5 mg nebulized x 1 dose. If effective (improved working of breathing, respiratory rate, wheezing, aeration) order scheduled albuterol 2-4 puffs with spacer or 2.5 mg nebulized q4h</td>
<td>Increased work of breathing</td>
</tr>
</tbody>
</table>
| **Prednisone or Methylprednisolone** | 1 mg/kg (maximum 40 mg/dose) PO/IV q12h x 5 days
Followed by steroid wean to prevent rebound:
  0.5 mg/kg (maximum 20 mg/dose) PO/IV q12h x 3 days
  0.5 mg/kg (maximum 20 mg/dose) PO/IV q24h x 3 days
  0.25 mg/kg (maximum 10 mg/dose) PO/IV q24h x 3 days | Consider in patients if wheezing/crackles/rales present or history of asthma |
| **Ranitidine**     | 1 mg/kg (maximum 150 mg/dose) PO q12h
OR
  1 mg/kg (maximum 50 mg/dose) IV q8h | GI prophylaxis for steroid use                       |
| **Furosemide**     | 0.5 – 1 mg/kg (maximum 40 mg/dose)                                    | Consider if signs of fluid overload present      |
## TABLE 4. PAIN MEDICATION

<table>
<thead>
<tr>
<th>Medication</th>
<th>Dosing</th>
<th>Indication</th>
</tr>
</thead>
</table>
| Acetaminophen | Dose according to manufacturer’s recommendations  
Maximum daily dose 75 mg/kg/day or 4,000 mg/day | Temperature greater than or equal to 38.3°C    |
| Ketorolac    | 0.5 mg/kg (maximum 30 mg/dose) IV q6h x 48 hours                       | Pain/Inflammation                               |
| Ibuprofen    | 10 mg/kg (maximum 600 mg/dose) PO q6 after 48-hours of ketorolac completed  
Maximum daily dose 2.4 g/day | Pain/Inflammation                               |
| Morphine     | **Intermittent Dosing:**  
0.1 – 0.15 mg/kg (maximum 8 mg/dose) IV x 1 dose followed by 0.05 – 0.15 mg/kg (maximum 4 mg/dose) IV q2-4hr  
**PCA Dosing:**  
PCA Dose: 0.01 – 0.02 mg/kg (maximum 10 mg/hr) with lockout of 8 minutes  
Continuous Rate: 0.03 – 0.05 mg/kg/hr | Pain                                             |
| Hydromorphone| **Intermittent Dosing:**  
0.015 – 0.02 mg/kg (maximum 2 mg/dose) followed by 0.015 – 0.02 mg/kg (maximum 1 mg/dose) q3-4hr  
**PCA Dosing:**  
PCA Dose: 2 – 3 mCg/kg (maximum dose 1.2 mg/hr) with a lockout of 1.2 mg/hr  
Continuous Rate: 3 – 5 mCg/kg/hr | Pain                                             |

## DISCHARGE CRITERIA

- Improved pulmonary symptoms and documentation of adequate oxygenation on room air
- Negative cultures for greater than or equal to 24-48 hours if applicable
- Stable hemoglobin/hematocrit
- Taking adequate oral fluids and able to take oral medications if applicable
- Adequate pain relief, if needed, with oral analgesics
- Follow-up plans coordinated with sickle cell team
- Pulmonology follow up arranged
REFERENCES

Clinical pathways are intended for informational purposes only. They are current at the date of publication and are reviewed on a regular basis to align with the best available evidence. Some information and links may not be available to external viewers. External viewers are encouraged to consult other available sources if needed to confirm and supplement the content presented in the clinical pathways. Clinical pathways are not intended to take the place of a physician’s or other health care provider’s advice, and is not intended to diagnose, treat, cure or prevent any disease or other medical condition. The information should not be used in place of a visit, call, consultation or advice of a physician or other health care provider. Furthermore, the information is provided for use solely at your own risk. CHCO accepts no liability for the content, or for the consequences of any actions taken on the basis of the information provided. The information provided to you and the actions taken thereof are provided on an “as is” basis without any warranty of any kind, express or implied, from CHCO. CHCO declares no affiliation, sponsorship, nor any partnerships with any listed organization, or its respective directors, officers, employees, agents, contractors, affiliates, and representatives.

CLINICAL IMPROVEMENT TEAM MEMBERS

Chris McKinney, MD | Hematology
Oren Kupfer, MD | Pulmonology
Rachelle Nuss, MD | Hematology
Joyce Baker, RT | Respiratory Therapist
Abby Kim, PharmD | Clinical Pharmacist
Paige Krack, MBA, MS | Process Improvement Lead

APPROVED BY

Clinical Care Guideline and Measures Review Committee – April 18, 2016
Antimicrobial Stewardship Committee – January 22, 2016
Pharmacy & Therapeutics Committee – February 10, 2016; minor revision March 2, 2017

<table>
<thead>
<tr>
<th>MANUAL/DEPARTMENT</th>
<th>Clinical Care Guidelines/Quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORIGINATION DATE</td>
<td>November 24, 2015</td>
</tr>
<tr>
<td>LAST DATE OF REVIEW OR REVISION</td>
<td>April 18, 2016</td>
</tr>
</tbody>
</table>
| APPROVED BY       | Lalit Bajaj, MD, MPH
                   | Medical Director, Clinical Effectiveness |

REVIEW/REVISION SCHEDULE

Scheduled for full review on April 18, 2020
Discrimination is Against the Law. Children's Hospital Colorado complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Children's Hospital Colorado does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex.

Children's Hospital Colorado provides free aids and services to people with disabilities to communicate effectively with us, such as: Qualified sign language interpreters, written information in other formats (large print, audio, accessible electronic formats, other formats). Children's Hospital Colorado provides free language services to people whose primary language is not English, such as: Qualified interpreters, information written in other languages.

If you need these services, contact the Medical Interpreters Department at 720-777-9800.

If you believe that Children's Hospital Colorado has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with: Corporate Compliance Officer, 13123 E. 10th Avenue, B450, Aurora, Colorado 80045, Phone: 720.777.1234, Fax: 720.777.7257, corporate.compliance@childrenscolordo.org. You can file a grievance in person or by mail, fax, or email. If you need help filling a grievance, the Corporate Compliance Officer is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at orbit.hhs.gov/ORC/lobbyist, or by mail or phone at: U.S. Department of Health and Human Services 20 Independence Avenue, SW Room 509F, HHFI Building Washington, D.C. 20201-2321, 800-368-1019, 800-537-7567 (TDD) Complaint forms are available at www.hhs.gov/ocr/office/fil/index.html.

Children's Hospital Colorado complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex.

ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1-720-777-9800.


주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 1-720-777-9800으로 전화해 주십시오.

注意：如果您使用繁體中文，您可以免費獲得語言援助服務。請致電1-720-777-9800。

ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 1-720-777-9800.

 важный пункт 1-720-777-9800 (по русскому языку) 

 заметка: 1-720-777-9800 (по русскому языку) 


 注意事項：日本語を話される場合、無料の言語支援をご利用いただけます。1-720-777-9800 まで、お電話にてご連絡ください。